OZEMPIC (SEMAGLUTIDE): A NEW WEIGHT LOSS DRUG FOR CHRONIC WEIGHT MANAGEMENT
Main Article Content
Keywords
Ozempic, Semaglutide, Weight Management new drug, A New Weight Loss Drug, Obesity new drug
Abstract
Background: Obesity is a chronic, relapsing disease that imposes significant costs on individuals, society, and the economy. Semaglutide is thought to cause weight loss by improving appetite control and, as a result, reducing energy intake through effects in the hypothalamus and the area postrema of the brain
Methodology: A numbers of 9 mice were subjected to semaglutide uptake, in King Abdulaziz medical city research laboratory، Riyadh, KSA.Data were analysed with statistical package of social sciences (SPSS).
Results: The results showed BW decreased by 22% at the highest dose tested (mean ± SEM, 100 nmol/kg from 43.6 ± 1.6 g to 34.8 ± 1.4 g) and 10% at the lowest dose tested (mean ± SEM, 1 nmol/kg, from 42.5 ± 1.3 g to 38.2 ± 1.3 g)
Conclusion: Fluorescently labelled semaglutide was detected in regions traditionally associated with GLP-1R-mediated food intake regulation, such as the hypothalamic ARH in the brainstem. The ARH mediates liraglutide-regulated food intake and weight loss through direct activation.
References
2. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. doi:10.1111/dom.14280
3. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. doi:10.1172/jci.insight.133429
4. O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. doi:10.1016/S0140-6736(18)31773-2
5. Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19:1242–51.doi:10.1111/dom.12932
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002.doi:10.1056/NEJMoa2032183
7. Davies M, Færch L, Jeppesen OK. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021;397:971–84.
8. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA 2021;325:1403–13.doi:10.1001/jama.2021.1831
9. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 2021;325:1414–25.doi:10.1001/jama.2021.3224
10. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity 2020;28:1050–61.doi:10.1002/oby.22794
11. Yutaka S, Yasuo T, Takeshi O, et al. Safety and efficacy of semaglutide once-weekly vs sitagliptin once-daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 2018;20:378–88.
12. Kohei K, Yuichira Y, Jirotaka W, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab 2018;20:1202–12.
13. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 2018;103:2291–301.doi:10.1210/jc.2018-00070
14. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The Lancet Diabetes Endocrinol 2019;7:356–67.doi:10.1016/S2213-8587(19)30066-X
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Khalid Abdullah Alsefri
Pharmacist, Alazizyah Children Hospital - Jeddah
Mohammed Ayed Alsefri
Pharmacy Technician, King Abdullah Medical Complex - Jeddah
Morad Ayed Alsefri
Pharmacy Technician, East Jeddah Hospital-Jeddah
Abdullah Salem Alharbi
Pharmacist, East Jeddah Hospital - Jeddah